Filter
Exclude
Time range
-
Near
Jon Blay retweeted
This is so exciting! BioAI just jumped a level with the release of ESMFold2! Kudos to Alex and the team for making this open scientific engine and releasing billions of proteins and predicted structures!
Today we're announcing ESMFold2, an open scientific engine to power prediction, design, and discovery across protein biology. The new model delivers state of the art performance on protein interactions, especially antibodies, a critical modality for therapeutics. We have designed and validated miniprotein binders and single chain antibodies across five therapeutic targets that are important in cancer and immunology. We are seeing very high success rates, and affinities at levels consistent with therapeutic activity. We’re also releasing an atlas of 6.8 billion proteins, and 1.1 billion predicted structures. ESMFold2 is built on a state of the art language model that has been trained on billions of protein sequences. A world model of protein biology emerges through language modeling. We’ve used the techniques of mechanistic interpretability developed to understand large language models to understand the concepts ESM uses to represent proteins. The model’s representation space has a compositional organization of features across scales, levels of complexity, and abstraction, that reflects and mirrors the understanding of protein biology developed through a century of empirical science. This understanding emerges without prior knowledge, just from language modeling of protein sequences. Language models are becoming a powerful substrate to understand and program biology. The design of protein interactions is one of the most fundamental problems in biophysics, and has critical implications for the discovery of new medicines. A simple gradient based search with the model was able to discover high-affinity protein binders. I'm excited by the potential this has to accelerate basic science and the understanding of proteins. And especially for the new avenues it opens up for therapeutic design and medicine.
1
19
137
23,655
everyone’s racing to build AI on text data. a new lab is quietly doing it on biological data. this is what the biotech x AI convergence actually looks like. watching closely 👀 #bioAI #syntheticbiology #longevity
Together with my co-founders Michael @MichaelPoli6, Stefano @Massastrello and Armin @athmsx, I am excited to announce @RadicalNumerics is emerging from stealth with a $50M seed round to build general biological intelligence. We’re also sharing an early preview of our new model Omnii, the most powerful genome language model to date. Omnii preview link: radicalnumerics.ai/blog/radi… At Radical Numerics, our mission is to master the code of life, and to drive the frontier of biological AI for both design and defense. This is our dual mandate, which comes from something our own team helped make possible. Our founding team trained Evo and Evo 2, the largest biological AI models (40B params) trained on DNA sequences. Trillions of tokens across all of life, from microbes to mammals. It’s fully open source, and created the field now known as generative genomics. Last year, scientists used Evo to generate the world’s first complete genome from scratch using AI. Turns out it was a bacteriophage—a type of virus. It functioned in the real world, and in this case it was harmless. But for us, it was a clear turning point. It showed that AI is no longer just analyzing biology. It is on the cusp of generating functional lifeforms. Eventually, AI will have the power to design and control life itself. That should make all of us incredibly excited, and incredibly uneasy. (Anyone can design DNA with a new function, and have it synthesized and delivered, like something from Amazon Prime). The same technology that will help us cure cancer is the very technology that might create the next global pandemic, or worse, allow the creation of bioweapons that can wipe out populations. We believe these forces are inseparable. If you work on the frontier of biology, you have to build technology to safeguard it from its misuse. Existing biosecurity tools are sorely losing the arms race, relying on outdated “have I seen this exact thing before?” style algorithms. We founded Radical Numerics to turn the tide. And we can’t do that by training on textbooks and natural language. We must understand the language of biology from the raw physical data itself, to reason across every molecule and modality, from DNA to proteins. The next frontier for AI goes far beyond chatbots or video generators to models that can understand and engineer life. Today, we’re previewing Omnii, which is already far surpassing Evo 2, and will continue improving as we scale and add new modalities (training now). 1. For human health, Omnii can read and write whole genomes (more on writing later). It’s state of the art (SOTA) on detecting causal variants for disease, and can rank Alzheimer's mutations zero-shot. We’re partnering with a diagnostics company to use Omnii for early cancer detection (pancreatic and multi-cancer). 2. For defense, Omnii is SOTA at detecting AI-generated pathogens. We benchmarked existing detection tools, and they simply can’t detect the AI-generated ones (“deepfake viruses”). We’re partnering with a US national lab to pilot Omnii for detecting the next pandemic, both natural and AI-generated. We have a data center full of Blackwells in construction now to build the most powerful biological AI models ever. This mission takes a new kind of AI lab that can actually scale on physical, biological data: new alignment research (mid/post training), scaling long context, building out mech interp teams to dissect what these models learn, new architectures and systems designs, all from the ground up. Our team is made up of AI researchers and scientists from top labs and institutions (e.g. Stanford, MIT, Google DeepMind), but more importantly, we all share the belief that this is the most important challenge of our lifetime. If you feel similarly, we are hiring. We aim to bring the brightest minds in AI and science together to save lives. Thanks to our partners on this journey, led by Emergence Capital @emergencecap, with Obvious Ventures @obviousvc, Triatomic @TriatomicCap , and Patrick Collison @patrickc. Our advisors include Eric Horvitz @erichorvitz, CSO of Microsoft, Chris Re @HazyResearch of Stanford, George Church @geochurch of Harvard, and Andrew Weber @AndyWeberNCB, former Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs. Fortune article: fortune.com/2026/06/15/exclu… Jobs: radicalnumerics.ai/join-us
1
5
179
wjmccartan-Billy retweeted
New era of human biology exploration! Perhaps bioAI models will soon reduce animal research.
The new Office of Research Innovation, Validation, and Application (ORIVA) will play a key role in helping NIH move towards reducing animal use in research while advancing the development of innovative technologies that better model human biology. ORIVA will coordinate NIH-wide efforts to develop, validate, and scale up the use of human-based approaches across our expansive biomedical research portfolio. Read more ➡️ bit.ly/4vPIYai
2
9
1,423
So excited to see what these guys do! BioAI is going to change how we invent cures and build technology.
Together with my co-founders Michael @MichaelPoli6, Stefano @Massastrello and Armin @athmsx, I am excited to announce @RadicalNumerics is emerging from stealth with a $50M seed round to build general biological intelligence. We’re also sharing an early preview of our new model Omnii, the most powerful genome language model to date. Omnii preview link: radicalnumerics.ai/blog/radi… At Radical Numerics, our mission is to master the code of life, and to drive the frontier of biological AI for both design and defense. This is our dual mandate, which comes from something our own team helped make possible. Our founding team trained Evo and Evo 2, the largest biological AI models (40B params) trained on DNA sequences. Trillions of tokens across all of life, from microbes to mammals. It’s fully open source, and created the field now known as generative genomics. Last year, scientists used Evo to generate the world’s first complete genome from scratch using AI. Turns out it was a bacteriophage—a type of virus. It functioned in the real world, and in this case it was harmless. But for us, it was a clear turning point. It showed that AI is no longer just analyzing biology. It is on the cusp of generating functional lifeforms. Eventually, AI will have the power to design and control life itself. That should make all of us incredibly excited, and incredibly uneasy. (Anyone can design DNA with a new function, and have it synthesized and delivered, like something from Amazon Prime). The same technology that will help us cure cancer is the very technology that might create the next global pandemic, or worse, allow the creation of bioweapons that can wipe out populations. We believe these forces are inseparable. If you work on the frontier of biology, you have to build technology to safeguard it from its misuse. Existing biosecurity tools are sorely losing the arms race, relying on outdated “have I seen this exact thing before?” style algorithms. We founded Radical Numerics to turn the tide. And we can’t do that by training on textbooks and natural language. We must understand the language of biology from the raw physical data itself, to reason across every molecule and modality, from DNA to proteins. The next frontier for AI goes far beyond chatbots or video generators to models that can understand and engineer life. Today, we’re previewing Omnii, which is already far surpassing Evo 2, and will continue improving as we scale and add new modalities (training now). 1. For human health, Omnii can read and write whole genomes (more on writing later). It’s state of the art (SOTA) on detecting causal variants for disease, and can rank Alzheimer's mutations zero-shot. We’re partnering with a diagnostics company to use Omnii for early cancer detection (pancreatic and multi-cancer). 2. For defense, Omnii is SOTA at detecting AI-generated pathogens. We benchmarked existing detection tools, and they simply can’t detect the AI-generated ones (“deepfake viruses”). We’re partnering with a US national lab to pilot Omnii for detecting the next pandemic, both natural and AI-generated. We have a data center full of Blackwells in construction now to build the most powerful biological AI models ever. This mission takes a new kind of AI lab that can actually scale on physical, biological data: new alignment research (mid/post training), scaling long context, building out mech interp teams to dissect what these models learn, new architectures and systems designs, all from the ground up. Our team is made up of AI researchers and scientists from top labs and institutions (e.g. Stanford, MIT, Google DeepMind), but more importantly, we all share the belief that this is the most important challenge of our lifetime. If you feel similarly, we are hiring. We aim to bring the brightest minds in AI and science together to save lives. Thanks to our partners on this journey, led by Emergence Capital @emergencecap, with Obvious Ventures @obviousvc, Triatomic @TriatomicCap , and Patrick Collison @patrickc. Our advisors include Eric Horvitz @erichorvitz, CSO of Microsoft, Chris Re @HazyResearch of Stanford, George Church @geochurch of Harvard, and Andrew Weber @AndyWeberNCB, former Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs. Fortune article: fortune.com/2026/06/15/exclu… Jobs: radicalnumerics.ai/join-us
1
14
1,896
Insiders know bioai has been making a chain of breakthroughs in the last few years - just like LLMs during the pre/ChatGPT period . We are rapidly approaching the ChatGPT moment for biology and I'm convinced @RadicalNumerics is the team that is going to make it happen.
Together with my co-founders Michael @MichaelPoli6, Stefano @Massastrello and Armin @athmsx, I am excited to announce @RadicalNumerics is emerging from stealth with a $50M seed round to build general biological intelligence. We’re also sharing an early preview of our new model Omnii, the most powerful genome language model to date. Omnii preview link: radicalnumerics.ai/blog/radi… At Radical Numerics, our mission is to master the code of life, and to drive the frontier of biological AI for both design and defense. This is our dual mandate, which comes from something our own team helped make possible. Our founding team trained Evo and Evo 2, the largest biological AI models (40B params) trained on DNA sequences. Trillions of tokens across all of life, from microbes to mammals. It’s fully open source, and created the field now known as generative genomics. Last year, scientists used Evo to generate the world’s first complete genome from scratch using AI. Turns out it was a bacteriophage—a type of virus. It functioned in the real world, and in this case it was harmless. But for us, it was a clear turning point. It showed that AI is no longer just analyzing biology. It is on the cusp of generating functional lifeforms. Eventually, AI will have the power to design and control life itself. That should make all of us incredibly excited, and incredibly uneasy. (Anyone can design DNA with a new function, and have it synthesized and delivered, like something from Amazon Prime). The same technology that will help us cure cancer is the very technology that might create the next global pandemic, or worse, allow the creation of bioweapons that can wipe out populations. We believe these forces are inseparable. If you work on the frontier of biology, you have to build technology to safeguard it from its misuse. Existing biosecurity tools are sorely losing the arms race, relying on outdated “have I seen this exact thing before?” style algorithms. We founded Radical Numerics to turn the tide. And we can’t do that by training on textbooks and natural language. We must understand the language of biology from the raw physical data itself, to reason across every molecule and modality, from DNA to proteins. The next frontier for AI goes far beyond chatbots or video generators to models that can understand and engineer life. Today, we’re previewing Omnii, which is already far surpassing Evo 2, and will continue improving as we scale and add new modalities (training now). 1. For human health, Omnii can read and write whole genomes (more on writing later). It’s state of the art (SOTA) on detecting causal variants for disease, and can rank Alzheimer's mutations zero-shot. We’re partnering with a diagnostics company to use Omnii for early cancer detection (pancreatic and multi-cancer). 2. For defense, Omnii is SOTA at detecting AI-generated pathogens. We benchmarked existing detection tools, and they simply can’t detect the AI-generated ones (“deepfake viruses”). We’re partnering with a US national lab to pilot Omnii for detecting the next pandemic, both natural and AI-generated. We have a data center full of Blackwells in construction now to build the most powerful biological AI models ever. This mission takes a new kind of AI lab that can actually scale on physical, biological data: new alignment research (mid/post training), scaling long context, building out mech interp teams to dissect what these models learn, new architectures and systems designs, all from the ground up. Our team is made up of AI researchers and scientists from top labs and institutions (e.g. Stanford, MIT, Google DeepMind), but more importantly, we all share the belief that this is the most important challenge of our lifetime. If you feel similarly, we are hiring. We aim to bring the brightest minds in AI and science together to save lives. Thanks to our partners on this journey, led by Emergence Capital @emergencecap, with Obvious Ventures @obviousvc, Triatomic @TriatomicCap , and Patrick Collison @patrickc. Our advisors include Eric Horvitz @erichorvitz, CSO of Microsoft, Chris Re @HazyResearch of Stanford, George Church @geochurch of Harvard, and Andrew Weber @AndyWeberNCB, former Assistant Secretary of Defense for Nuclear, Chemical and Biological Defense Programs. Fortune article: fortune.com/2026/06/15/exclu… Jobs: radicalnumerics.ai/join-us
1
10
537
城ヶ崎ノアのbioAIイラストレーターなの死ね
106
Anna Thompson retweeted
Oh i see, yes, people who have never legit lived as who they actually are not bioAI
1
5
36
Keith Robison retweeted
RTing this to prove that I've been bitching about bioAI refusals since before it was cool
At the Asilomar conference in 1975, biologists chose to be pro-active about calling their own work risky 50 years later, you can’t ask AI for a PCR recipe without getting shut down like a bioterrorist My fellow biologists: this is our fault. We built this regulatory culture
3
1
21
1,888
Anthony M. Hopper retweeted
We hope to do this BioAI show with Peter on a bi-weekly schedule. Today’s topic, starting shortly, is the fabled fable 5. ☺️
First BAIO Show today with @DeryaTR_ We’re going to talk Claude Fable. It might get emotional. Join us here: x.com/i/spaces/1pKkOOeaEyZKj
1
2
31
5,133
AI Is Rewriting mRNA Drug Design The success of COVID-19 mRNA vaccines proved that messenger RNA can become a transformative therapeutic platform. Yet one of the field’s biggest challenges remains unresolved: How do we design the optimal mRNA sequence among billions of possibilities? A new review in Journal of Advanced Research highlights how artificial intelligence is rapidly becoming the engine that drives next-generation mRNA therapeutics. Unlike conventional drugs, mRNA performance depends heavily on sequence architecture: • 5′ untranslated region (5′UTR) • Coding sequence (CDS) • 3′ untranslated region (3′UTR) • Secondary structure • Codon usage patterns Even when two mRNAs encode exactly the same protein, differences in sequence design can dramatically alter: ✓ Translation efficiency ✓ Stability ✓ Immunogenicity ✓ Tissue-specific expression The review describes a major paradigm shift. Generation 1: Rule-based optimization Historically, mRNA engineering relied on: • Codon adaptation indices • Kozak sequence tuning • Empirical UTR selection • Trial-and-error screening These approaches explore only tiny regions of an enormous design space. For example, the synonymous coding space of the SARS-CoV-2 spike protein exceeds 10⁶³² possible mRNA sequences. Generation 2: AI prediction models Deep-learning systems such as: • Optimus 5-Prime • UTR-LM • CodonBERT • mRNABERT learn sequence–function relationships directly from large experimental datasets. Rather than relying on hand-crafted rules, these models predict: • Ribosome loading • Translation efficiency • mRNA half-life • Protein expression output Generation 3: AI-generated mRNA The most exciting development is the rise of generative design. Instead of evaluating existing sequences, AI can now create entirely new ones. Examples include: 🧬 UTRGAN 🧬 Smart5UTR 🧬 PARADE 🧬 GEMORNA These systems generate synthetic UTRs and coding sequences optimized for specific objectives such as: • High expression • Increased stability • Reduced immunogenicity • Cell-type specificity Some AI-designed UTRs produced: 🚀 Up to 34-fold increases in translation efficiency 🚀 Nearly 100-fold higher vaccine-induced antibody responses compared with conventional designs. The next frontier: coordinated design The review argues that the field is moving beyond isolated optimization of individual sequence elements. Current efforts increasingly focus on: 5′UTR CDS 3′UTR co-design as a unified system. Models such as: • LinearDesign2 • GEMORNA • mRNABERT attempt to optimize the entire transcript simultaneously rather than treating each region independently. This matters because translation, stability, structure, and immunogenicity emerge from interactions across the full-length mRNA molecule. Why this matters The future of mRNA medicine may resemble modern protein design. Instead of manually optimizing sequence elements, researchers will specify desired properties: ✓ High expression ✓ Long half-life ✓ Low innate immune activation ✓ Liver targeting ✓ Efficient LNP delivery and AI systems will generate candidate mRNAs automatically. The authors envision a future built around: • Foundation models for RNA biology • Multi-objective optimization • Generative AI • Closed-loop design-build-test-learn platforms where computational models and experimental validation continuously improve each other. If protein engineering was transformed by AlphaFold and generative biology, mRNA therapeutics may be approaching a similar inflection point. The next blockbuster mRNA drug may be designed not by manual codon tuning—but by AI. Reference Shi Y, Zeng C, Sheng X, et al. Transforming mRNA drug design with AI: From UTR and codon optimization to coordinated design. Journal of Advanced Research (2026) DOI: 10.1016/j.jare.2026.06.013 #mRNA #ArtificialIntelligence #GenerativeAI #CodonOptimization #UTRDesign #RNAEngineering #DrugDiscovery #BioAI #PrecisionMedicine #JournalOfAdvancedResearch
1
6
340
Replying to @MartinShkreli
So bioAI '26 is like Quantums '25? I'm fine with that
1
1
269
Replying to @liangc_science
interesting post. thank you. The anti-scaling law impacts some parts of the potential value creation and value capture areas of your industry (the old Economies of Scale Industry and the blue area in this picture?). But there are ofc. value creation and value capture models for long tails too. Eg. the grey area of this picture marks the Asset turnover ratio/CFROI margin of Amazon some years ago. there must be thousands of Food Biotech and Fungi BioAI startups already who target the long tail and the Economies of Scope and Niche Demand Aggregation there. My Finnmycel is one of those.
224
Great conference about algorithms underlying current computational approaches in biology #BDBio2026 at CDS dept @iiscbangalore . Fantastic organisation by Chirag and Debnath, thoroughly enjoyed the interactions. A lot of interesting ideas around #bioAI, while also emphasizing the many fundamental biological questions that remain unsolved. Presented our recent results in cancer genomics and it was great to discuss a new direction our lab is taking. More coming soon.
2
4
51
3,440
DeSci-AI / BioAI 👀👇@paulkhls
We've made a breakthrough in self-evolving AI scientists moving from "search" to "principled discovery": Scientific discovery requires that the search space itself changes, and an AI scientist must perceive this shift without intervention. We built an AI that achieves this for the first time with the ability to discover the scientific vocabulary it reasons in. Evidence, tools, artifacts, verifiers, failures & claims become typed provenance. We show three distinct modalities: 1) retrieval, adding known objects; 2) search, exploring a fixed schema; and critically: 3) discovery, a verified regime transition. We solve the open-endedness evaluation problem by lifting agentic workflows into a typed copresheaf and proving, via a Kan obstruction, that true discovery is not unbounded generation but a verifiable schema expansion: old evidence is transported by Left Kan extension, and genuine novelty is mathematically quantified by the pointwise residual beyond the transported image - separating discovery from mere search and making novelty objective and measurable rather than a subjective judgment or benchmark delta. Our AI scientist is built in a way that does not pre-conceive the approach it chooses; instead, we endow the system with formal power to adapt, evolve, and reason from first principles. Case studies include: 1⃣Builder/Breaker model that discovers mode-conditioned compliance in proteins; 2⃣CategoryScienceClaw that finds anisotropic fiber-network stiffness rules. Great work in collaboration with my graduate student @fwang108_ @MITdeptofBE F.Y. Wang & M.J. Buehler, Self-Revising Discovery Systems for Science: A Categorical Framework for Agentic Artificial Intelligence, arXiv:2606.01444, 2026
2
4
158
AI-Integrated Immune Cell Delivery: The Next Frontier in Cancer Therapy A major bottleneck in cancer nanomedicine is that most delivery systems are still designed through labor-intensive trial-and-error approaches. A new review in the Journal of Controlled Release argues that the future lies in combining immune-cell delivery platforms with artificial intelligence (AI), creating adaptive and predictive therapeutic systems capable of overcoming tumor heterogeneity and immune suppression. Immune cells possess natural tumor-homing capabilities that conventional nanoparticles struggle to replicate. This review systematically compares five major immune-cell delivery platforms: 🔹 Macrophages – excellent for deep tumor penetration, stromal remodeling, and delivery into hypoxic regions. 🔹 Neutrophils – ideal for rapid recruitment to inflamed tumors, postoperative recurrence, and circulating tumor cell interception. 🔹 Dendritic Cells (DCs) – specialized for antigen presentation and immune priming, making them attractive for cancer vaccines. 🔹 Natural Killer (NK) Cells – provide rapid cytotoxicity and can be engineered through membrane coating or CAR-NK approaches. 🔹 T Cells – combine active trafficking with antigen-specific immune killing and remain central to advanced cell therapies such as CAR-T. The review highlights a paradigm shift: from empirical carrier design toward AI-integrated frameworks built around three pillars: 1️⃣ AI-Assisted Rational Design Machine learning models optimize CAR architectures. Generative AI platforms design proteins, peptides, and delivery vehicles. AI-guided CAR-T engineering can predict exhaustion and improve persistence before experimental validation. 2️⃣ Precision Target Identification Deep learning predicts TCR–neoantigen interactions. Models such as pMTnet identify highly immunogenic targets from patient-specific tumor mutations. Computational approaches enable rapid screening of tumor-specific antigens that are difficult to discover experimentally. 3️⃣ Predictive Delivery Assessment AI predicts pharmacokinetics, biodistribution, tumor homing, and toxicity. Integration of spatial transcriptomics and multi-omics data enables simulation of delivery performance before clinical testing. Emerging digital-twin frameworks may eventually support personalized dosing strategies. Particularly notable are examples such as: AI-guided multi-antigen CAR-T optimization achieving complete tumor clearance in preclinical models. De novo-designed pMHC minibinders generated using RFdiffusion and AlphaFold. CAR-Toner, an AI platform predicting tonic signaling and CAR exhaustion based on protein structural features. Yet significant challenges remain. Current AI systems suffer from limited standardized datasets, poor interpretability, manufacturing constraints, and insufficient modeling of the dynamic tumor microenvironment. The authors emphasize that future progress will require integrating immunology, nanotechnology, systems biology, spatial omics, and machine learning into unified platforms. The central message is clear: The next generation of cancer therapeutics will not simply use immune cells as carriers. Instead, AI will help design, optimize, predict, and personalize immune-cell delivery systems—transforming them from biologically inspired tools into intelligent therapeutic platforms. Reference Chen H, Dang X, Zhu J, et al. Immune cell delivery platforms for tumor therapy: From empirical approaches to AI-integrated frameworks. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.115065. #CancerResearch #Immunotherapy #CAR_T #CellTherapy #Nanomedicine #DrugDelivery #ArtificialIntelligence #MachineLearning #TumorMicroenvironment #PrecisionMedicine #JournalOfControlledRelease #BioAI #TranslationalMedicine #Oncology #CancerMetastasis
2
5
157